Physician

Nathan Paul Reed, D.O.

According to 2025 Medicare claims, Nathan Reed, D.O. (NPI: 1306066634) practices ophthalmology in the Muskegon-Norton Shores, MI market, with the plurality of this provider's patient population coming from Muskegon, MI. This provider's primary affiliated billing organization is SHORELINE OPHTHALMOLOGY, PLLC (NPI: 1679643670; TIN: 38-3245641) and primary practice location at 49444-1837. Reed is affiliated with the POM ACO (ACO ID: A1297) and West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Reed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 583 traditional Medicare patients, billed 1,419 HCPCS/CPT codes, and received $136,971 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,931 prescription claims across 839 beneficiaries totaling $313,614 in drug costs, led by Rocklatan (Netarsudil Mesylat/Latanoprost). 2022 DME data shows 51 claims. Open Payments data shows 6 records totaling $157. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $247,960 to $136,971. In contrast, Part D prescription costs have moved sharply higher in recent years, from $114,707 to $313,614. For DME billing, this smaller-volume category changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	932	2,349	$247,960
2016	869	1,952	$185,724
2017	819	2,105	$242,424
2018	785	1,911	$207,941
2019	898	2,064	$215,989
2020	698	1,639	$156,279
2021	783	1,881	$192,688
2022	734	1,850	$178,480
2023	647	1,582	$161,440
2024	583	1,419	$136,971

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	518	2,408	$114,707
2016	525	2,521	$104,753
2017	587	2,711	$128,468
2018	553	2,640	$164,215
2019	642	2,869	$207,881
2020	639	2,862	$216,161
2021	646	2,601	$236,062
2022	663	2,923	$298,165
2023	804	3,465	$326,018
2024	839	3,931	$313,614

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	118	118	$7,646
2016	53	53	$3,428
2017	91	91	$6,482
2018	69	69	$4,954
2019	80	80	$5,327
2020	18	18	$948
2021	49	49	$3,463
2022	51	51	$3,345
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	191	270	$79
92014	Established patient complete exam of visual system	261	271	$74
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	102	122	$57
92136	Measurement of corneal curvature and depth of eye	89	152	$24
92133	Imaging of optic nerve	98	112	$22

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rocklatan	Netarsudil Mesylat/Latanoprost	197	6,738	$83,091
Lumigan	Bimatoprost	129	7,149	$56,322
Restasis	Cyclosporine	22	1,290	$24,920
Latanoprost	Latanoprost	1,312	81,847	$20,783
Prednisolone Acetate	Prednisolone Acetate	343	15,089	$18,437

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$157	Alcon Vision LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nathan Paul Reed, D.O.?

Tedicare shows public-source Medicare data for Nathan Paul Reed, D.O. (NPI 1306066634), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nathan Paul Reed, D.O. have ACO affiliation data?

Nathan Paul Reed, D.O. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Nathan Paul Reed, D.O.?

Nathan Paul Reed, D.O. is linked to SHORELINE OPHTHALMOLOGY, PLLC (billing NPI 1679643670) in the available physician profile data.

Does Nathan Paul Reed, D.O. have Open Payments data?

Nathan Paul Reed, D.O. has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.